Embecta (NASDAQ:EMBC) Stock Rating Lowered by Wall Street Zen

by · The Cerbat Gem

Embecta (NASDAQ:EMBC – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a report released on Friday.

A number of other brokerages also recently issued reports on EMBC. Weiss Ratings reiterated a “hold (c-)” rating on shares of Embecta in a report on Wednesday, October 8th. Zacks Research lowered shares of Embecta from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 7th. Finally, BTIG Research reaffirmed a “buy” rating on shares of Embecta in a report on Tuesday. One equities research analyst has rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Embecta has a consensus rating of “Hold” and an average target price of $19.00.

View Our Latest Report on EMBC

Embecta Price Performance

EMBC opened at $12.75 on Friday. Embecta has a 12 month low of $9.20 and a 12 month high of $21.48. The stock has a market capitalization of $745.94 million, a P/E ratio of 7.82, a P/E/G ratio of 0.72 and a beta of 1.10. The business has a 50 day simple moving average of $13.92 and a 200-day simple moving average of $12.49.

Embecta (NASDAQ:EMBC – Get Free Report) last released its quarterly earnings data on Tuesday, November 25th. The company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.04. Embecta had a negative return on equity of 24.62% and a net margin of 8.83%.The firm had revenue of $263.30 million during the quarter, compared to analysts’ expectations of $265.66 million. During the same quarter in the prior year, the business posted $0.45 earnings per share. Embecta’s revenue was down 7.7% compared to the same quarter last year. Embecta has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts anticipate that Embecta will post 2.85 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of EMBC. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its holdings in Embecta by 7.9% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 15,005 shares of the company’s stock worth $145,000 after purchasing an additional 1,093 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Embecta by 5.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,589 shares of the company’s stock valued at $209,000 after buying an additional 1,110 shares during the last quarter. CWM LLC grew its position in shares of Embecta by 16.0% during the second quarter. CWM LLC now owns 8,080 shares of the company’s stock worth $78,000 after buying an additional 1,115 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Embecta by 2.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,323 shares of the company’s stock worth $629,000 after buying an additional 1,159 shares during the last quarter. Finally, SummerHaven Investment Management LLC raised its holdings in Embecta by 1.9% in the second quarter. SummerHaven Investment Management LLC now owns 66,313 shares of the company’s stock valued at $643,000 after acquiring an additional 1,268 shares in the last quarter. 93.83% of the stock is owned by hedge funds and other institutional investors.

About Embecta

(Get Free Report)

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.

Further Reading